Loading cancer entity…
Loading cancer entity…
Variants & evidence
7 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT4 Amplification1 | ||||||||
| Pazopanib | Angiosarcoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID5911One patient with angiosarcoma was initially treated with sorafenib, an inhibitor of VEGFR2, and developed progressive disease. The patient then received pazopanib, an inhibitor of VEGFR2 and VEGFR3 an… (full text at CIViC) PMID 27160228 · Ravi et al., 2016 · Open in CIViC | civic |
| KDR A1065T1 | ||||||||
| Sorafenib + SunitinibSubstitutes | Angiosarcoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1106COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type c… (full text at CIViC) PMID 19723655 · Antonescu et al., 2009 · Open in CIViC | civic |
| KDR Amplification1 | ||||||||
| Pazopanib | Angiosarcoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7139The angiosarcoma harbored amplifications of VEGFR2 (KDR) of 8 copies and VEGFR3 (FLT4) of 16 copies. The patient was initially treated with sorafenib, an inhibitor of VEGFR2, and developed progressive… (full text at CIViC) PMID 27160228 · Ravi et al., 2016 · Open in CIViC | civic |
| KDR D717V1 | ||||||||
| Sorafenib + SunitinibSubstitutes | Angiosarcoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1107COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type ce… (full text at CIViC) PMID 19723655 · Antonescu et al., 2009 · Open in CIViC | civic |
| KDR Overexpression1 | ||||||||
| Sunitinib | Breast Angiosarcoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID5910gene expression assay performed earlier demonstrated a This case report of a patient with refractory breast angiosarcoma shows a potential therapeutic benefit of sunitinib due to the upregulation of V… (full text at CIViC) PMID 25639617 · Silva et al., 2015 · Open in CIViC | civic |
| PTPRB Loss-of-function2 | ||||||||
| (diagnostic) | Angiosarcoma | Diagnostic | B | Supports Positive | 3 | accepted | EID10079A cohort of angiosarcomas (n=36) was sequenced and revealed to contain recurrent mutations in PTPRB (10/36) which were predominantly truncating or splice variants which impact the tyrosine phosphotase… (full text at CIViC) PMID 24633157 · Behjati et al., 2014 · Open in CIViC | civic |
| Sunitinib + VatalanibSubstitutes | Angiosarcoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1895The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplificatio… (full text at CIViC) PMID 24633157 · Behjati et al., 2014 · Open in CIViC | civic |
Data updated 1 hour agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.